Szu-chun F. Yang

138 Sheng Li Road, 704
Tainan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer.

Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: May 22, 2026

QIM26-284: Practice-Level Variation in ECOG Performance Status Documentation in Advanced Non-Small Cell Lung Cancer.

QIM26-284: Practice-Level Variation in ECOG Performance Status Documentation in Advanced Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Correction: Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.

Correction: Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.

Journal: PharmacoEconomics

Published: December 17, 2025

Cost-Effectiveness of Combination Amivantamab-Lazertinib, Osimertinib Plus Chemotherapy, and Osimertinib Monotherapy in Lung Cancer.

Cost-Effectiveness of Combination Amivantamab-Lazertinib, Osimertinib Plus Chemotherapy, and Osimertinib Monotherapy in Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 22, 2025

Validation of the Test of Adherence to Inhalers (TAI) among Taiwanese Patients with Chronic Obstructive Pulmonary Disease.

Validation of the Test of Adherence to Inhalers (TAI) among Taiwanese Patients with Chronic Obstructive Pulmonary Disease.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: June 13, 2025

Biomarker-Specific Survival and Medication Cost for Patients With Non-Small Cell Lung Cancer.

Biomarker-Specific Survival and Medication Cost for Patients With Non-Small Cell Lung Cancer.

Journal: JAMA network open

Published: June 10, 2025

Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Limited-Stage SCLC.

Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Limited-Stage SCLC.

Journal: JTO clinical and research reports

Published: April 04, 2025

BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer.

BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.

Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.

Journal: Cancer medicine

Published: March 05, 2025

Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer.

Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: December 09, 2024

Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.

Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.

Journal: PharmacoEconomics

Published: December 01, 2024

Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer.

Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer.

Journal: Therapeutic advances in medical oncology

Published: October 10, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026